Denise Scots-Knight
Fondateur chez MEREO BIOPHARMA GROUP PLC
Fortune : 3 M $ au 30/06/2024
Profil
Denise Vera Scots-Knight is the founder and the Chief Executive Officer & Director of Mereo BioPharma Group Plc, which was founded in 2015.
She is currently a Director at Mereo BioPharma 3 Ltd., Mereo BioPharma 2 Ltd., Elanco Animal Health, Inc., Mereo BioPharma 4 Ltd., and the President of Mereo BioPharma 5, Inc. Dr. Scots-Knight previously held positions as the Chairman-Supervisory Board of Nabriva Therapeutics GmbH from 2007 to 2016, Managing Director at Nomura International Plc from 1999 to 2010, and Independent Director at Idenix Pharmaceuticals LLC from 2003 to 2014.
She also served as an Independent Director at Mereo BioPharma 5, Inc. from 2008 to 2018 and as a Managing Partner at Phase4 Partners Ltd.
from 2010 to 2016.
Dr. Scots-Knight has a background in undergraduate studies from the University of California, Berkeley and the University of Birmingham, where she obtained both an undergraduate and a doctorate degree.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/06/2024 | 3 547 590 ( 0,51% ) | 3 M $ | 30/06/2024 | |
| 30/11/2023 | 60 231 ( 0,01% ) | 869 133 $ | 30/06/2024 |
Postes actifs de Denise Scots-Knight
| Sociétés | Poste | Début |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Fondateur | 10/07/2015 |
| ELANCO ANIMAL HEALTH INCORPORATED | Directeur/Membre du Conseil | 11/03/2019 |
| ONCOMED PHARMACEUTICALS INC | President | 23/04/2019 |
Mereo BioPharma 2 Ltd.
 Mereo BioPharma 2 Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mereo BioPharma Group Plc, Mereo BioPharma 2 Ltd. is a British company that provides research and experimental development for biotechnology. The company is based in London, UK and was founded in 2015. | Directeur/Membre du Conseil | 18/06/2015 |
Mereo Biopharma 3 Ltd.
 Mereo Biopharma 3 Ltd. BiotechnologyHealth Technology Part of Mereo BioPharma Group Plc, Mereo Biopharma 3 Ltd. develops bio pharm products. The company is based in London, UK. | Directeur/Membre du Conseil | - |
Mereo BioPharma 4 Ltd.
 Mereo BioPharma 4 Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mereo BioPharma Group Plc, Mereo BioPharma 4 Ltd. is a British biotechnology company founded in 2017 that provides research and development services. The company is based in London, UK. | Directeur/Membre du Conseil | 24/10/2017 |
Anciens postes connus de Denise Scots-Knight
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOMED PHARMACEUTICALS INC | Directeur/Membre du Conseil | 28/09/2018 |
| ALBIREO PHARMA, INC. | Directeur/Membre du Conseil | 28/09/2017 |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Président | 01/08/2016 |
| ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Denise Scots-Knight
| University of Birmingham | Doctorate Degree |
| University of California, Berkeley | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| ELANCO ANIMAL HEALTH INCORPORATED | Health Technology |
| Entreprise privées | 16 |
|---|---|
Phase4 Partners Ltd.
 Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Finance |
DeveloGen AG
 DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
| Rothschild Asset Management Ltd. | Miscellaneous |
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
| British Heart Foundation | Commercial Services |
Cerimon Pharmaceuticals, Inc.
 Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Mereo Biopharma 3 Ltd.
Mereo Biopharma 3 Ltd. BiotechnologyHealth Technology Part of Mereo BioPharma Group Plc, Mereo Biopharma 3 Ltd. develops bio pharm products. The company is based in London, UK. | Health Technology |
Mereo BioPharma 2 Ltd.
Mereo BioPharma 2 Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mereo BioPharma Group Plc, Mereo BioPharma 2 Ltd. is a British company that provides research and experimental development for biotechnology. The company is based in London, UK and was founded in 2015. | Commercial Services |
Nomura International Plc
 Nomura International Plc Investment Banks/BrokersFinance Nomura International Plc provides a variety of financial services including advisement, investment banking and asset management. It trades in and sells fixed income and equity products, including related derivatives; and provides investment banking services, and corporate finance and private equity services. The company is also involved in asset and principal finance business. It offers investment advisory and management, custody, and employment services. Nomura International was founded in 1981 and is headquartered in London, the United Kingdom. | Finance |
Mereo BioPharma 4 Ltd.
Mereo BioPharma 4 Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mereo BioPharma Group Plc, Mereo BioPharma 4 Ltd. is a British biotechnology company founded in 2017 that provides research and development services. The company is based in London, UK. | Commercial Services |
